Market Intelligence, Clinical Progress, and High-Purity Reagents for MAPK-Pathway Targeted Therapy and Drug Resistance Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RSK2/RSK3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RSK2 (RPS6KA3) Active Kinase / Mutant Protein High purity (>90%), Endotoxin <1EU/ug. Sequence Verified. |
View RSK2 Products |
| Antigen | RSK3 (RPS6KA4) Active Kinase High purity (>90%), Sf9 or E. coli expressed. Sequence Verified. |
View RSK3 Products |
| Gene Delivery | RSK2 (RPS6KA3) Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View RSK2 Products |
| Benchmark Ab | Anti-RSK2/RSK3 Recombinant Antibody Recombinant positive control for Western Blot and IP. |
View RSK2 Products |
| Validator | RSK2 (RPS6KA3) siRNA Set For knockdown verification in phenotypic assays. |
View RSK2 Products |
| Related Target A | ERK1 (MAPK3) Upstream activating kinase in the MAPK cascade; key for RSK activation assays. |
View MAPK3 Products |
| Related Target B | MEK1 (MAP2K1) Upstream regulator; critical for co-targeting studies to overcome MAPK pathway resistance. |
View MAP2K1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform selectivity screening (RSK1-4 homology) | Active recombinant RSK1, RSK2, RSK3, and RSK4 proteins available for parallel selectivity profiling. |
| High-throughput screening of covalent/non-covalent inhibitors | Sequence-verified kinase domains with optimized phosphorylation status and high purity (>90% by SDS-PAGE). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and selective tool compounds included. |
| False Positives | Validated siRNA sets included for target knockdown and specificity verification. |
Live RSK2 / RSK3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RSK2/RSK3 therapeutics is intensifying, with major players shifting focus from traditional broad kinase inhibitors to highly selective covalent inhibitors and allosteric modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting bypass resistance in MAPK-driven tumors, particularly in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Covalent) | Phoenix Molecular Designs, Boehringer Ingelheim | Triple-Negative Breast Cancer (TNBC), NSCLC | Selectivity Assay (Need active RSK1-4 panel to confirm isoform specificity) |
| Small Molecule (Non-covalent) | Academic Institutions, Biotech Startups | Prostate Cancer, Coffin-Lowry Syndrome (activation studies) | Kinase Activity Assay (Need highly active WT proteins with native phosphorylation) |
| PROTAC / Degrader | Targeted Protein Degradation Biotechs | Drug-Resistant Solid Tumors | Ternary Complex Validation (Need high-purity, sequence-verified RSK2/RSK3 proteins) |